Myopia control is a set of treatments designed to slow the worsening of nearsightedness in children, not just correct it. Standard glasses and contact lenses sharpen a child’s vision right now, but they do nothing to prevent the eye from continuing to grow longer over time. Myopia control interventions actively work to reduce that growth, which matters because the longer an eye becomes, the higher the lifetime risk of serious eye diseases.
The distinction is important. About 27% of the world’s population was nearsighted in 2010, and projections estimate that figure will reach 52%, nearly 5 billion people, by 2050. With that surge comes a parallel rise in vision-threatening complications, making treatments that slow progression in childhood a significant focus of modern eye care.
Why Slowing Myopia Matters More Than Correcting It
Nearsightedness isn’t just an inconvenience solved by stronger glasses each year. It’s driven by the physical lengthening of the eyeball. As the eye stretches, the retina thins, the optic nerve faces more mechanical stress, and the internal structures become increasingly fragile. These changes are permanent and cumulative.
The consequences scale with severity. People with high myopia (generally defined as a prescription of negative 5 diopters or stronger) face dramatically elevated risks: they are five to six times more likely to develop a retinal detachment compared to those with mild nearsightedness. The risk of glaucoma is roughly 2.5 times higher in moderate to high myopia. Myopic macular degeneration, a leading cause of irreversible vision loss, rises sharply with both increasing prescription strength and age. Every diopter of progression avoided in childhood translates to meaningfully lower odds of these problems decades later.
How the Eye Decides to Keep Growing
The eye has a built-in feedback system that adjusts its length during childhood to bring images into sharp focus on the retina. When the signals go wrong, the eye overshoots and grows too long, producing myopia. One key driver appears to be what happens at the edges of vision. Standard single-vision glasses correct the center of the visual field but leave the peripheral retina slightly out of focus in a way that signals “keep growing.” This peripheral blur acts as a chemical trigger: it sets off a cascade that changes the structural tissue at the back of the eye, making the wall of the eyeball more pliable and allowing it to stretch further.
Most myopia control treatments exploit this same feedback system in reverse. By projecting light slightly in front of the peripheral retina rather than behind it, they create the opposite signal, one that tells the eye to slow down or stop elongating. Different devices accomplish this in different ways, but the core principle is the same: change the pattern of light hitting the retina’s edges to override the “grow longer” message.
Specialized Glasses for Myopia Control
The newest category of myopia control is spectacle lenses engineered with tiny structures embedded across the lens surface. These lenses look like normal glasses but contain hundreds of small lenslets that redirect peripheral light to create a volume of defocused light in front of the retina. The center of the lens still provides a clear, sharp image for reading and distance vision.
One well-studied design using highly aspherical lenslets showed strong long-term results. Over five years, children wearing these lenses progressed 1.75 diopters less than predicted for children in standard glasses, and their eyes grew 0.72 mm less. For many families, specialized glasses are the most approachable option because they require no drops, no contact lens handling, and no change in a child’s daily routine beyond wearing a different pair of frames.
Contact Lens Options
Soft contact lenses designed for myopia control use a dual-focus approach: the center of the lens corrects distance vision normally, while concentric rings in the periphery create the myopic defocus that slows eye growth. The most widely studied version is a daily disposable lens. In a six-year clinical trial, children who wore these lenses from the start accumulated 0.52 mm less eye growth than untreated children. Their growth rate stayed close to what would be expected in children who weren’t nearsighted at all. Treated eyes took almost four years longer to reach the same amount of growth that untreated eyes reached, essentially buying years of slower progression.
Orthokeratology, often called ortho-k, takes a different approach. Children wear rigid, specially shaped lenses overnight that gently reshape the front surface of the eye while they sleep. During the day, they see clearly without any glasses or contacts. Beyond the convenience factor, ortho-k also reshapes peripheral light focus in a way that slows elongation. One study found a 70% reduction in eye growth over 12 months compared to standard glasses. The lenses must be worn consistently each night, and the reshaping effect is temporary, so skipping nights means blurry daytime vision and reduced control.
Atropine Eye Drops
Low-dose atropine drops are a pharmacological option, typically used as a nightly eye drop. Unlike the other treatments, atropine doesn’t change how light enters the eye. Instead, it appears to act directly on the chemical signaling pathways that regulate eye growth, though the exact mechanism is still being refined.
Concentration matters. In a clinical trial comparing two low doses, the 0.05% concentration cut prescription worsening to about 0.26 diopters over the study period compared to 0.76 diopters in the untreated group, roughly a 65% reduction. The 0.01% concentration also worked but was less potent, with progression of about 0.32 diopters. Side effects are minimal at these low doses, mostly slight pupil dilation and minor light sensitivity, far less than the full-strength atropine used for other eye conditions.
Atropine is often combined with optical methods like specialized contacts or glasses, and there’s good reason for that beyond simply stacking treatments. This combination appears to help with one of atropine’s biggest drawbacks: rebound.
The Rebound Problem
When children stop atropine drops, the eye can accelerate its growth beyond what would have happened without treatment. This rebound effect is most pronounced in the first six months after stopping. In one major study, children who discontinued a higher concentration of atropine progressed at more than a diopter per year during the washout period, roughly triple the rate of untreated children. Even at lower doses, 68% of children who stopped 0.05% atropine progressed by at least half a diopter in the following year.
Several factors make rebound worse: stopping treatment abruptly, younger age at discontinuation, shorter treatment durations, and higher starting prescriptions. A gradual stepdown in dose helps but doesn’t eliminate the issue entirely. The most promising approach appears to be pairing atropine with an optical treatment like myopia control contact lenses. In one study, children using both atropine and dual-focus contacts maintained a progression rate of just 0.18 diopters per year after stopping atropine, nearly identical to their rate during active treatment. This suggests the optical component can act as a safety net during the transition off drops.
When to Start and How Long to Continue
Younger children progress fastest. The research is clear that the earlier a child becomes nearsighted, the more their prescription will worsen over time, which means starting treatment sooner produces better cumulative results. Evidence supports beginning myopia control as early as age 4 for atropine drops, age 6 for ortho-k, ages 7 to 8 for soft contact lenses, and age 8 for specialized spectacle lenses.
A common mistake is waiting to see whether a child’s prescription gets worse before starting treatment. Every child with myopia under age 16 is likely to show progression. The window for intervention is finite, and each year of uncontrolled growth adds length to the eye that can’t be reversed. Treatment generally continues until myopia stabilizes, which for most children means through the mid-to-late teenage years, sometimes into the early twenties.
Outdoor Time as a Protective Factor
Time spent outdoors is one of the simplest protective factors against myopia development and progression. The current recommendation is roughly two hours of outdoor time per day. The benefit appears to come from exposure to bright, natural light rather than from physical activity itself. Bright light stimulates the release of compounds in the retina that help regulate eye growth, and the optical environment outdoors, with its long viewing distances and broad, even illumination, is fundamentally different from the close-up, dim conditions of indoor life.
Outdoor time is most effective as prevention before myopia develops, but it still plays a supporting role alongside active treatments in children who are already nearsighted. It’s the one intervention with no cost, no side effects, and no prescription required.